Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 May 27;63(20):2069-2078.
doi: 10.1016/j.jacc.2014.01.016. Epub 2014 Feb 12.

Inotropes

Affiliations
Free article
Review

Inotropes

Gary S Francis et al. J Am Coll Cardiol. .
Free article

Abstract

Inotropes have been fundamental to resuscitation of acute cardiogenic shock for decades. Heart failure and cardiogenic shock, in severe cases, are syndromes characterized in many patients by a reduction in myocardial contractile force. While inotropes successfully increase cardiac output, their use has been plagued by excessive mortality due to increased tachycardia and myocardial oxygen consumption leading to arrhythmia and myocardial ischemia. There is a pressing need for new inotropic agents that avoid these harmful effects. This review describes the mechanism of action and the clinical utility of some of the older inotropic agents, which are still commonly used, and provides an update for physicians on the development of newer inotropic drugs. The field is rapidly changing, and it is likely that new agents will be designed that improve systolic performance without necessarily increasing the myocardial oxygen consumption.

Keywords: acute heart failure; cardiogenic shock; inotrope.

PubMed Disclaimer

Similar articles

  • A Review of Inotropes and Inopressors for Effective Utilization in Patients With Acute Decompensated Heart Failure.
    Nandkeolyar S, Ryu R, Mohammad A, Cordero-Caban K, Abramov D, Tran H, Hauschild C, Stoletniy L, Hilliard A, Sakr A. Nandkeolyar S, et al. J Cardiovasc Pharmacol. 2021 Sep 1;78(3):336-345. doi: 10.1097/FJC.0000000000001078. J Cardiovasc Pharmacol. 2021. PMID: 34117179 Review.
  • Cardiogenic shock: Inotropes and vasopressors.
    Amado J, Gago P, Santos W, Mimoso J, de Jesus I. Amado J, et al. Rev Port Cardiol. 2016 Dec;35(12):681-695. doi: 10.1016/j.repc.2016.08.004. Epub 2016 Nov 8. Rev Port Cardiol. 2016. PMID: 27836218 Review. English, Portuguese.
  • Treatments targeting inotropy.
    Maack C, Eschenhagen T, Hamdani N, Heinzel FR, Lyon AR, Manstein DJ, Metzger J, Papp Z, Tocchetti CG, Yilmaz MB, Anker SD, Balligand JL, Bauersachs J, Brutsaert D, Carrier L, Chlopicki S, Cleland JG, de Boer RA, Dietl A, Fischmeister R, Harjola VP, Heymans S, Hilfiker-Kleiner D, Holzmeister J, de Keulenaer G, Limongelli G, Linke WA, Lund LH, Masip J, Metra M, Mueller C, Pieske B, Ponikowski P, Ristić A, Ruschitzka F, Seferović PM, Skouri H, Zimmermann WH, Mebazaa A. Maack C, et al. Eur Heart J. 2019 Nov 21;40(44):3626-3644. doi: 10.1093/eurheartj/ehy600. Eur Heart J. 2019. PMID: 30295807 Free PMC article.
  • The current and future status of inotropes in heart failure management.
    Arfaras-Melainis A, Ventoulis I, Polyzogopoulou E, Boultadakis A, Parissis J. Arfaras-Melainis A, et al. Expert Rev Cardiovasc Ther. 2023 Jul-Dec;21(8):573-585. doi: 10.1080/14779072.2023.2237869. Epub 2023 Jul 23. Expert Rev Cardiovasc Ther. 2023. PMID: 37458248 Review.
  • Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F. Follath F. Ital Heart J. 2003 May;4 Suppl 2:34S-38S. Ital Heart J. 2003. PMID: 14635368 Clinical Trial.

Cited by

MeSH terms

Substances